Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°í·É ȯÀÚ¿Í ½Å¼±Áֱ⠹è¾ÆÀ̽Ŀ¡¼­ Àӽſ¡ ½ÇÆÐÇÑ È¯ÀÚ¿¡¼­ µ¿°á-À¶ÇØ ¹è¾ÆÀ̽ÄÀÇ È¿¿ë¼º Efficacy of Frozen-Thawed ET in Patients with Old Age or Non-Pregnant in Fresh ET Cycles

´ëÇѺÒÀÓÇÐȸÁö 2006³â 33±Ç 4È£ p.237 ~ 243
ÃÖ¼öÁø, À̼±Èñ, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ÀüÁøÇö,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ¼öÁø ( Choi Su-Jin ) 
Á¦ÀϺ´¿ø »ý½Ä»ý¹°ÇÐ ¹× ºÒÀÓ¿¬±¸½Ç

À̼±Èñ ( Lee Sun-Hee ) 
Á¦ÀϺ´¿ø »ý½Ä»ý¹°ÇÐ ¹× ºÒÀÓ¿¬±¸½Ç
¼ÛÀοÁ ( Song In-Ok ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀϺ´¿ø »êºÎÀΰú
±Ã¹Ì°æ ( Koong Mi-Kyoung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀϺ´¿ø »êºÎÀΰú
°­Àμö ( Kang Inn-Soo ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø »êºÎÀΰú
ÀüÁøÇö ( Jun Jin-Hyun ) 
Á¦ÀϺ´¿ø »ý½Ä»ý¹°ÇÐ ¹× ºÒÀÓ¿¬±¸½Ç

Abstract

¸ñ Àû: µ¿°á-À¶ÇØ ¹è¾ÆÀ̽ÄÀº º¸Á¶»ý½Ä¼ú¿¡¼­ ȯÀڵ鿡°Ô º¸´Ù ¸¹Àº ÀÓ½ÅÀÇ ±âȸ¸¦ Á¦°øÇØÁÙ ¼ö ÀÖ´Â ¹æ¹ýÀ¸·Î ÀÌ¿ëµÇ°í ÀÖ´Ù. º» ¿¬±¸¿¡¼­´Â ¿¹ÈÄ°¡ ÁÁÁö ¾ÊÀº ȯÀڵ鿡¼­ µ¿°á-À¶ÇØ ¹è¾ÆÀ̽ÄÀÇ È¿¿ë¼ºÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¿¬±¸¹æ¹ý: ³ªÀÌ°¡ ¸¹Àº °í·É ȯÀÚ±º (38~44¼¼)°ú ½Å¼±Áֱ⠹è¾ÆÀ̽Ŀ¡¼­ ÀӽŠ½ÇÆбºÀ» ¿¬±¸´ë»óÀ¸·Î ÇÏ¿´´Ù. °ú¹è¶õ À¯µµ¸¦ ÅëÇØ Ã¤ÃëÇÑ ³­ÀÚ¸¦ ÀϹÝÀûÀΠü¿Ü¼öÁ¤ ¶Ç´Â ¼¼Æ÷Áú³» Á¤ÀÚÁÖÀÔ¼úÀ» ½ÃÇàÇÏ¿© ¼öÁ¤À» À¯µµÇÏ°í, À׿©ÀÇ ÀüÇÙ ¶Ç´Â ³­ÇÒ ½Ã±âÀÇ ¹è¾Æ¸¦ ¿Ï¸¸µ¿°á¹ýÀ¸·Î µ¿°áÇÏ¿´´Ù. µ¿°áº¸°ü ¹è¾Æ´Â ±Þ¼ÓÀ¶ÇعýÀ¸·Î À¶ÇØÇÏ¿© È£¸£¸ó¿ä¹ýÀ» ½ÃÇàÇÑ È¯ÀÚÀÇ Àڱÿ¡ À̽ÄÇÏ¿´´Ù. ½Å¼± ¹è¾ÆÀ̽İú µ¿°á-À¶ÇØ ¹è¾ÆÀÌ½Ä °úÁ¤¿¡¼­ÀÇ ¹è¾Æ »óÅÂ, ÀÓ½ÅÀ², Âø»ó·ü µîÀ» Åë°èÀûÀÎ ¹æ¹ýÀ¸·Î ºÐ¼®ÇÏ¿´´Ù.

°á °ú: ³ªÀÌ°¡ ¸¹Àº °í·É±º¿¡¼­ ½Å¼± ¹è¾ÆÀ̽ÄÀ» ½ÃÇàÇÑ È¯ÀÚµé°ú µ¿°á-À¶ÇØ ¹è¾ÆÀ̽ÄÀ» ½ÃÇàÇÑ È¯ÀÚµéÀÇ Æò±Õ ¿¬·ÉÀº 40.0¡¾1.8¼¼ (n=206)¿Í 39.9¡¾1.9¼¼ (n=69)·Î Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸³ª, ÀÓ»óÀû ÀÓ½ÅÀ²°ú Âø»ó·üÀº µ¿°á-À¶ÇØ ¹è¾ÆÀ̽Ŀ¡¼­ 29.0%¿Í 11.2%·Î ½Å¼± ¹è¾ÆÀ̽ÄÀÇ 16.5%¿Í 7.0%¿¡ ºñÇØ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³ô°Ô ³ªÅ¸³µ´Ù (p<0.05). ù¹ø° ½Å¼± ¹è¾ÆÀ̽Ŀ¡¼­ ÀӽŠ½ÇÆбºÀÇ ¿¬¼ÓµÇ´Â ½Å¼± ¹è¾ÆÀÌ½Ä È¯ÀÚ±º (31.2¡¾2.3, n=40)°ú µ¿°á-À¶ÇØ ¹è¾ÆÀÌ½Ä È¯ÀÚ±º (31.9¡¾3.1, n=119)¿¡¼­ÀÇ Æò±Õ ¿¬·ÉÀº Â÷ÀÌ°¡ ¾ø¾úÀ¸¸ç, ÀÓ»óÀû ÀÓ½ÅÀ² (42.5% vs 40.3%)°ú Âø»ó·ü (22.6% vs 18.8%)µµ À¯»çÇÏ¿´´Ù.

°á ·Ð: º» ¿¬±¸¿¡¼­´Â µ¿°á-À¶ÇØ ¹è¾ÆÀ̽ÄÀÌ °í·É ȯÀڵ鿡¼­ È¿°úÀûÀ¸·Î ÀÓ½ÅÀ²°ú Âø»ó·üÀ» ³ôÀÏ ¼ö ÀÖÀ½À» º¸¿©ÁÖ°í ÀÖ´Ù. ÀÌ·¯ÇÑ °á°ú´Â °ú¹è¶õ À¯µµ¿¡ µû¸¥ ÀÚ±ÃÀÇ Âø»ó ȯ°æ º¯È­°¡ °í·É ȯÀڵ鿡¼­ ÀÓ½ÅÀ²°ú Âø»ó·üÀ» ÀúÇϽÃÅ°´Â °Í°ú °ü·ÃÀÌ ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ´Ù.

Objective: The aim of this study was to evaluate the efficacy of frozen-thawed ET in poor prognosis patients such as the old age (38~44 years; OA group) and the patients who did not achieve clinical pregnancy with the first fresh ET cycle (non-pregnant patients; NP group).

Methods: Laboratory and clinical data were collected from fresh and frozen-thawed ET cycles of OA and NP group. Controlled ovarian hyperstimulation (COH) and conventional insemination or ICSI, in vitro culture and ET were performed by routine procedures. Supernumerary embryos were frozen by the slow freezing
method, and frozen embryos were thawed by the rapid thawing method. Embryo development, pregnancy and implantation rates were statistically analyzed by Student t-test and chi square test.

Results: Mean ages were similar between fresh ET (40.0¡¾1.8 years, n=206) and frozen-thawed ET (39.9¡¾1.9 years, n=69) cycles in OA group. However, the clinical pregnancy and implantation rate of subsequent
frozen-thawed ET significantly higher than those of fresh ET cycles (29.0% and 11.2% vs. 16.5% and 7.0%, p<0.05). In NP group, there was no difference in the mean age between fresh ET (31.2¡¾2.3 years, n=40) and frozen-thawed ET (31.9¡¾3.1 years, n=119) in subsequent cycles. The clinical pregnancy and implantation rates were similar between the subsequent fresh ET (42.5% and 22.6%) and the frozen-thawed ET (40.3% and 18.8%).

Conclusion: In old age patients, higher pregnancy rate of frozen-thawed ET compared to fresh ET cycles in this study. It may be related that better uterine environments for implantation in frozen-thawed ET cycles than that of non-physiological hormonal condition in uterus of fresh COH cycles.

Å°¿öµå

Frozen-thawed ET;Clinical pregnancy;COH;Implantation

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS